It suggested that SLC35A2 was highly expressed in 16 cancers [LUAD, LIHC, cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), PRAD, GBM, HNSC, BLCA, LUSC, cholangiocarcinoma (CHOL), STAD, UCEC, rectum adenocarcinoma (READ), PAAD, BRCA, COAD, and ESCA] than in adjacent healthy tissues (P < 0.05, Figure 2A). This evidence concerns the gene SLC35A2 and prostate adenocarcinoma.